Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
CanSino Biologics, Inc. Class H ( (HK:6185) ) has issued an announcement.
CanSino Biologics Inc. has established a Nomination Committee to enhance its corporate governance by standardizing the nomination procedures for directors and senior management. This move aims to improve the board’s composition and align with relevant regulations, potentially strengthening the company’s governance structure and market position.
The most recent analyst rating on (HK:6185) stock is a Hold with a HK$41.00 price target. To see the full list of analyst forecasts on CanSino Biologics, Inc. Class H stock, see the HK:6185 Stock Forecast page.
More about CanSino Biologics, Inc. Class H
CanSino Biologics Inc. is a biopharmaceutical company based in China, focusing on the research, development, and commercialization of innovative vaccines for human use. The company is listed on the STAR Market of the Shanghai Stock Exchange and the Stock Exchange of Hong Kong, indicating its focus on both domestic and international markets.
Average Trading Volume: 2,081,073
Technical Sentiment Signal: Buy
Current Market Cap: HK$13.13B
For detailed information about 6185 stock, go to TipRanks’ Stock Analysis page.